The request is broader than rival pharmaceutical company
Pfizer’s request earlier this week for the regulator to approve a booster shot
for all seniors.
In a press release, the company said its request for
approval for all adults was made “to provide flexibility” to the Centers for
Disease Control and Prevention and medical providers to determine the
“appropriate use” of a second booster dose of the mRNA vaccine, “including for
those at higher risk of COVID-19 due to age or comorbidities.”
U.S. officials have been laying the groundwork to deliver
additional booster doses to shore up the vaccines’ protection against serious
disease and death from COVID-19. The White House has been sounding the alarm
that it needs Congress to “urgently” approve more funding for the federal
government to secure more doses of the COVID-19 vaccines, either for additional
booster shots or variant-specific immunizations.
U.S. health officials currently recommend a primary series
of two doses of the Moderna vaccine and a booster dose months later.
Moderna said its request for an additional dose was based on
“recently published data generated in the United States and Israel following the
emergence of Omicron.”
On Tuesday, Pfizer and its partner BioNTech asked U.S. regulators to authorize an additional booster dose of their COVID-19 vaccine for seniors, saying data from Israel suggests older adults would benefit.
0 comments:
Post a Comment